RGEN

Repligen Corporation (RGEN) | Rumor.io

Repligen

RGEN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,865

Bullish sentiment (50-day avg)100%

Price to earnings ratio263.4

Market capitalization11B

Earnings per share0.72

Dividend yield (TTM)—

Revenue (annual)738.3M

Net income (annual)48.9M

Social

What share of all stock conversation is about RGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jul 28

Repligen Corporation (RGEN) reported Q2 2026 revenue of $204M, a 12% increase year-over-year, with 13% organic growth and a 55% surge in adjusted operating income.
The company raised its FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, beating estimates.
Repligen's stock price rose ~14.6% after the earnings release, and the company announced a definitive agreement to acquire BioLife Solutions for $1.5B.

Generated by AI

Sentiment

Of the messages about RGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	80.04% +10.12
Bearish	—	0% 0	0% 0	19.96% -10.12

Apr 27

Repligen Corporation's Q1 results beat expectations, with revenue growth of 71.70% YoY and EPS of $0.92, up 57% YoY.
The company has reported a record revenue quarter, with a strong Q1 earnings beat that led to a 10% stock price increase.
Repligen's strong fundamentals, including a 43% YoY increase in revenue per share, have attracted significant institutional investment, with Assenagon Asset Management increasing their holdings by 551%.

Generated by AI

Topics

Of the messages about RGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	47.06%	46%	57.85%
Technical Analysis	100%	52.94%	54%	28.49%
Earnings	0%	0%	0%	10.27%
Analysts	0%	0%	0%	1.37%
Controversies	0%	0%	0%	0.07%
Macro	0%	0%	0%	1.95%

Earnings· Apr 27

Repligen Corporation ($RGEN) reported Q1 EPS of $0.92, beating consensus estimates by $0.20.
The company's revenue for Q1 was $206.4M, beating consensus estimates by $20.92M.
Repligen lowered its FY22 EPS guidance to $3.07-$3.15, below consensus estimates, and revenue guidance to $770-800 million, below consensus estimates.

Announcements· Jul 22

Repligen Corporation ($RGEN) will acquire BioLife Solutions ($BLFS) in a cash-and-stock deal valued at approximately $1.5 billion, with BioLife stockholders receiving $11.25 in cash and 0.1442 Repligen shares per share.
The acquisition expands Repligen's presence in the cell therapy market, with BioLife's biopreservation media and cell processing tools complementing Repligen's offerings.
The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year, with Repligen's total enterprise value increasing to approximately $7.6 billion.

Generated by AI

Community

Of the messages about RGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	44.44%	26.09%	21.52%	57.86%
Newcomers	55.56%	73.91%	78.48%	42.14%

Regulars· Jun 13

Repligen's CEO transition is causing a significant impact on the company's shares, with a -11.83% drop and increased put buys in peers like DHR and A.
The CEO transition plan involves Tony J. Hunt stepping down and becoming Executive Chair, with Olivier Loeillot taking over as President and CEO, effective September 1, 2024.
The news of the CEO transition is driving above-average trading volume, with Repligen Corporation traded 192% above its average volume.

Newcomers· Jul 28

Repligen Corporation ($RGEN) reported a 12% year-over-year increase in revenue to $204 million in Q2, with adjusted income from operations increasing 55%.
The company raised its FY26 organic growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, with a strong bioprocessing recovery and margin expansion confirmed.
$RGEN shares are trading higher after the company's Q2 results beat expectations, with a transformative deal announced and a strong buy thesis emerging due to the bioprocessing recovery and strategic move.

Generated by AI

News

Repligen announces long-serving director Karen Dawes’ retirement

Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

13d agoThe Globe and Mail

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

18d agoSeeking Alpha

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

20d agoInvesting.com

Also Discussed

Investors talking about RGEN also mention

#	Name	Attention
1	Fortune Brands Innovations Inc.FBIN	0%0
2	Stevanato Group S.p.A.STVN	0%0
3	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
4	Regenxbio Inc.RGNX	0%+0
5	ICON plcICLR	0%0
6	Danaher Corp.DHR	0.02%+0.02
7	Thermo Fisher Scientific Inc.TMO	0%0
8	Veeva Systems Inc.VEEV	0%0
9	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
10	MaxCyte, Inc.MXCT	0%0

Repligen Corporation

Healthcare
Medical Instruments & Supplies

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies. Its products are used by biopharmaceutical companies and contract development and manufacturing organizations to improve efficiency, control, and consistency in production processes. The company offers consumables and instruments such as Protein A ligands, chromatography columns, filtration systems, and analytical tools designed for biologics processing. Headquartered in Waltham, Massachusetts, Repligen Corporation serves customers across North America, Europe, the Asia Pacific, and other international markets, making it an important supplier within the bioprocessing and life sciences tools sector.

Website

Location

Building 1

Waltham, MA, 02453

United States

Social

What share of all stock conversation is about RGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jul 28

Repligen Corporation (RGEN) reported Q2 2026 revenue of $204M, a 12% increase year-over-year, with 13% organic growth and a 55% surge in adjusted operating income.
The company raised its FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, beating estimates.
Repligen's stock price rose ~14.6% after the earnings release, and the company announced a definitive agreement to acquire BioLife Solutions for $1.5B.

Generated by AI

Sentiment

Of the messages about RGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	80.04% +10.12
Bearish	—	0% 0	0% 0	19.96% -10.12

Apr 27

Repligen Corporation's Q1 results beat expectations, with revenue growth of 71.70% YoY and EPS of $0.92, up 57% YoY.
The company has reported a record revenue quarter, with a strong Q1 earnings beat that led to a 10% stock price increase.
Repligen's strong fundamentals, including a 43% YoY increase in revenue per share, have attracted significant institutional investment, with Assenagon Asset Management increasing their holdings by 551%.

Generated by AI

Topics

Of the messages about RGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	47.06%	46%	57.85%
Technical Analysis	100%	52.94%	54%	28.49%
Earnings	0%	0%	0%	10.27%
Analysts	0%	0%	0%	1.37%
Controversies	0%	0%	0%	0.07%
Macro	0%	0%	0%	1.95%

Earnings· Apr 27

Repligen Corporation ($RGEN) reported Q1 EPS of $0.92, beating consensus estimates by $0.20.
The company's revenue for Q1 was $206.4M, beating consensus estimates by $20.92M.
Repligen lowered its FY22 EPS guidance to $3.07-$3.15, below consensus estimates, and revenue guidance to $770-800 million, below consensus estimates.

Announcements· Jul 22

Repligen Corporation ($RGEN) will acquire BioLife Solutions ($BLFS) in a cash-and-stock deal valued at approximately $1.5 billion, with BioLife stockholders receiving $11.25 in cash and 0.1442 Repligen shares per share.
The acquisition expands Repligen's presence in the cell therapy market, with BioLife's biopreservation media and cell processing tools complementing Repligen's offerings.
The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year, with Repligen's total enterprise value increasing to approximately $7.6 billion.

Generated by AI

Community

Of the messages about RGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	44.44%	26.09%	21.52%	57.86%
Newcomers	55.56%	73.91%	78.48%	42.14%

Regulars· Jun 13

Repligen's CEO transition is causing a significant impact on the company's shares, with a -11.83% drop and increased put buys in peers like DHR and A.
The CEO transition plan involves Tony J. Hunt stepping down and becoming Executive Chair, with Olivier Loeillot taking over as President and CEO, effective September 1, 2024.
The news of the CEO transition is driving above-average trading volume, with Repligen Corporation traded 192% above its average volume.

Newcomers· Jul 28

Repligen Corporation ($RGEN) reported a 12% year-over-year increase in revenue to $204 million in Q2, with adjusted income from operations increasing 55%.
The company raised its FY26 organic growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, with a strong bioprocessing recovery and margin expansion confirmed.
$RGEN shares are trading higher after the company's Q2 results beat expectations, with a transformative deal announced and a strong buy thesis emerging due to the bioprocessing recovery and strategic move.

Generated by AI

Repligen

Social

Jul 28

Apr 27

Earnings· Apr 27

Announcements· Jul 22

Regulars· Jun 13

Newcomers· Jul 28

Repligen CEO Olivier Loeillot sells $976,680 in company stock

Repligen CEO Loeillot sells $2.46m in shares

Repligen Corporation stock hits 52-week high at 188.95 USD

Repligen announces long-serving director Karen Dawes’ retirement

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

Also Discussed

Repligen Corporation

Company Information

Location

Repligen CEO Olivier Loeillot sells $976,680 in company stock

Repligen CEO Loeillot sells $2.46m in shares

Repligen Corporation stock hits 52-week high at 188.95 USD

Repligen announces long-serving director Karen Dawes’ retirement

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

Also Discussed

Social

Jul 28

Apr 27

Earnings· Apr 27

Announcements· Jul 22

Regulars· Jun 13

Newcomers· Jul 28